Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-04-24 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
第三届监事会第十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on various agenda items including approval of the 2024 annual report, financial statements, dividend plans, and other related reports. The document references multiple reports that have been or will be published separately on the Beijing Stock Exchange website, indicating this document itself is not the full reports but a meeting resolution summary. The document length is under 5,000 characters and primarily serves as an official announcement of meeting decisions and approvals, not the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) rather than the actual Annual Report (10-K) or other detailed reports.
2025-04-24 Chinese
2024年度独立董事述职报告（李良琛已离职）
Board/Management Information Classification · 95% confidence The document is titled '2024 年度独立董事述职报告' which translates to '2024 Annual Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance, and activities during the year 2024. The content includes the director's background, attendance at board and shareholder meetings, supervisory activities, and self-evaluation. It is not an announcement of a meeting, voting results, or a financial report. It is a management-related report focusing on governance and director duties rather than financial results or audit. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board members and their activities. The document length is 3101 characters, which is sufficient for a detailed report but not a full annual report or audit report. Hence, the classification is MANG with high confidence.
2025-04-24 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management assurances about the accuracy of the report. The report covers the period from January to March 2025, indicating it is a quarterly financial report. The document is over 11,000 characters long, contains substantive financial data and analysis, and is unaudited as stated. These characteristics align with the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-24 Chinese
变更部分募集资金用途及募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding changes in the use of previously raised funds and delays in investment projects. It includes specifics about the original and revised use of funds, investment amounts, project descriptions, reasons for changes, and approvals from the board and supervisory committees. The document focuses on fundraising proceeds usage and project timelines, which aligns with updates on company fundraising and capital structure changes. It is not a full financial report, earnings release, or management discussion, nor is it a simple announcement of a report publication. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7155 characters) and detailed content support this classification with high confidence.
2025-04-24 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary." It contains detailed financial data for the year 2024, including assets, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy and completeness of the report, an audit opinion from an accounting firm, and dividend distribution plans. The content is comprehensive and covers company operations, financial performance, shareholder structure, and other key annual report elements. The document length is over 6,000 characters, indicating it is not a mere announcement or a brief summary but a substantive report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-24 Chinese
关于董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the 2024 annual performance of the Board Audit Committee of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the committee's activities, meetings, evaluations of financial reports, and oversight of external auditors during the 2024 fiscal year. The content focuses on the audit committee's duties and their fulfillment, including review and supervision of financial reporting and audit work. It is not a full annual report (10-K), nor is it a standalone audit report (AR) in the traditional sense, but rather a report on the audit committee's performance and activities. This type of document aligns with Audit Report / Information (AR) category, which includes reports on audit committee activities and audit-related oversight. The document is 2442 characters long, which is relatively short but contains substantive content about audit committee duties and evaluations, not merely an announcement or certification. Therefore, the best fit is AR with high confidence. FY 2024
2025-04-24 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.